Abstract: Provided in the present invention is a novel inhibitor of FLT3 kinase, comprising a compound of formula (I) or a pharmaceutically acceptable salt, solvate, isomer, ester, acid, metabolite or prodrug thereof. Also provided in the present invention are a pharmaceutical composition comprising a compound of formula (I) and a use and method for preventing or treating cell proliferative conditions and/or FLT3-related conditions, in particular for conditions responding to the inhibition of FLT3 kinase (especially FLT3/ITD mutant kinases).
Type:
Grant
Filed:
August 7, 2015
Date of Patent:
April 23, 2019
Assignees:
HEFEI INSTITUTES OF PHYSICAL SCIENCE, CHINESE ACADEMY OF SCIENCES, HEFEI COSOURCE PHARMACEUTICAL CO., LTD.
Inventors:
Jing Liu, Qingsong Liu, Xixiang Li, Aoli Wang, Hong Wu, Cheng Chen, Wenchao Wang, Chen Hu, Zheng Zhao, Jiaxin Wu, Juan Liu, Kailin Yu, Wei Wang, Li Wang, Beilei Wang
Abstract: Provided in the present invention is a novel inhibitor of FLT3 kinase, comprising a compound of formula (I) or a pharmaceutically acceptable salt, solvate, isomer, ester, acid, metabolite or prodrug thereof. Also provided in the present invention are a pharmaceutical composition comprising a compound of formula (I) and a use and method for preventing or treating cell proliferative conditions and/or FLT3-related conditions, in particular for conditions responding to the inhibition of FLT3 kinase (especially FLT3/ITD mutant kinases).
Type:
Application
Filed:
August 7, 2015
Publication date:
February 1, 2018
Applicants:
HEFEI INSTITUTES OF PHYSICAL SCIENCE, CHINESE ACADEMY OF SCIENCES, HEFEI COSOURCE PHARMACEUTICAL CO., LTD.
Inventors:
Jing LIU, Qingsong LIU, Xixiang LI, Aoli WANG, Hong WU, Cheng CHEN, Wenchao WANG, Chen HU, Zheng ZHAO, Jiaxin WU, Juan LIU, Kailin YU, Wei WANG, Li WANG, Beilei WANG